Announcements Trials

Browse Landscape

Phase

Status

Completed 18 Terminated 12 Unknown 5 Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 12 Neuroendocrine Tumors 5 Neoplasm Metastasis 5 Carcinoma, Renal Cell 4 Triple Negative Breast Neoplasms 3 Adenoma, Islet Cell 3 Recurrence 2 Meningioma 2 Glioblastoma 2 Diffuse Intrinsic Pontine Glioma 2 Carcinoma, Hepatocellular 2 Carcinoid Tumor 2 von Hippel-Lindau Disease 1 Unilateral Breast Neoplasms 1 Tuberous Sclerosis 1 Thymus Neoplasms 1 Sarcoma 1 Neoplasms 1 Metastatic Digestive System Neuroendocrine Tumor G1 1 Lymphangioleiomyomatosis 1 Locally Advanced Thyroid Gland Carcinoma 1 Kidney Neoplasms 1 HR+/HER2- Advanced Breast Cancer 1 Glioma 1 Gastroenteropancreatic Neuroendocrine Tumors 1 Gastro-enteropancreatic neuroendocrine tumor 1 Gallbladder Neoplasms 1 Disease Progression 1 Colorectal Neoplasms 1 Brain Neoplasms 1

Interventions

Blood Specimen Collection 38 pembrolizumab 36 Bevacizumab 22 Surveys and Questionnaires 18 Standard of Care 18 Radiotherapy 18 Exercise 17 Carboplatin 16 Nivolumab 15 atezolizumab 14 Cisplatin 14 Drug Therapy 13 Paclitaxel 12 Fluorouracil 12 Cyclophosphamide 12 Cetuximab 12 Trastuzumab 10 Leucovorin 10 Docetaxel 10 Dexamethasone 10 Pemetrexed 9 Oxaliplatin 9 Biopsy 9 pertuzumab 8 olaparib 8 Temozolomide 8 Panitumumab 8 Observation 8 Irinotecan 8 abemaciclib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasms × Everolimus × Clear all

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡